anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Mobile health (mHealth) solutions can improve the quality, accessibility, and equity of health services, fostering early rehabilitation. For individuals with hearing loss, mHealth apps might be designed to support the decision-making processes in auditory diagnostics and provide treatment recommendations to the user (eg, hearing aid need). For some individuals, such an mHealth app might be the first contact with a hearing diagnostic service and should motivate users with hearing loss to seek professional help in a targeted manner. However, personalizing treatment recommendations is only possible by knowing the individual's profile regarding the outcome of interest.
OBJECTIVE: This study aims to characterize individuals who are more or less prone to seeking professional help after the repeated use of an app-based hearing test. The goal was to derive relevant hearing-related traits and personality characteristics for personalized treatment recommendations for users of mHealth hearing solutions.
METHODS: In total, 185 (n=106, 57.3% female) nonaided older individuals (mean age 63.8, SD 6.6 y) with subjective hearing loss participated in a mobile study. We collected cross-sectional and longitudinal data on a comprehensive set of 83 hearing-related and psychological measures among those previously found to predict hearing help seeking. Readiness to seek help was assessed as the outcome variable at study end and after 2 months. Participants were classified into help seekers and nonseekers using several supervised machine learning algorithms (random forest, naïve Bayes, and support vector machine). The most relevant features for prediction were identified using feature importance analysis.
RESULTS: The algorithms correctly predicted action to seek help at study end in 65.9% (122/185) to 70.3% (130/185) of cases, reaching 74.8% (98/131) classification accuracy at follow-up. Among the most important features for classification beyond hearing performance were the perceived consequences of hearing loss in daily life, attitude toward hearing aids, motivation to seek help, physical health, sensory sensitivity personality trait, neuroticism, and income.
CONCLUSIONS: This study contributes to the identification of individual characteristics that predict help seeking in older individuals with self-reported hearing loss. Suggestions are made for their implementation in an individual-profiling algorithm and for deriving targeted recommendations in mHealth hearing apps.
A method for the rational design and preparation of vaccines based on HIV envelope polypeptides is described. In one embodiment, the method for making an HIV gp120 subunit vaccine for a geographic region comprises determining neutralizing epitopes in the V2 and/or C4 domains of gp120 of HIV isolates from the geographic region and selecting an HIV strain having gp120 a neutralizing epitope in the V2 or C4-domain which is common among isolates in the geographic region. In a preferred embodiment of the method, neutralizing epitopes for the V2, V3, and C4 domains of gp120 are determined. At least two HIV isolates having different neutralizing epitopes in the V2, V3, or C4 domain are selected and used to make the vaccine. The invention also provides a multivalent HIV gp120 subunit vaccine. A DNA sequence encoding gp120 from preferred vaccine strains of HIV, GNE 8  and GNE 16 , expression constructs comprising the GNE 8 -gp120 and GNE 16 -gp120 encoding DNA under the transcriptional and translational control of a heterologous promoter, and isolated GNE 8 -gp120 and GNE 16 -gp120 are also described.
Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment, a dose of 15 μg/m²/day in the subsequent 7 days, followed by 30 μg/m²/day starting from Week 3 of treatment.
The invention discloses a microcapsule with functions of magnetic resonance imaging and microwave treatment of tumors and a preparation method thereof. The microcapsule with the functions of magnetic resonance imaging and microwave tumor treatment consists of a core and a core shell, wherein the core material comprises a microwave heating material and a magnetic resonance imaging material, and the core shell is a gelatin material. The diameter of the microcapsule is 0.5-50 μm, and the thickness of the shell layer of the microcapsule is 0.1-10 μm. The microcapsule of the invention is prepared by the following method: emulsification, coagulation reaction, crosslinking and washing; and obtaining the microcapsules of the wrapped microwave heating material and the magnetic resonance imaging material. The composition, size and shell thickness of the microcapsule of the invention are adjustable. The invention has simple process, mild preparation condition, good repeatability and wide application range. Under the action of microwaves, the core material microwave heating materials generate a large amount of heat through mutual collision, so that the temperature of local tissues is raised to achieve the aim of eliminating tumor cells.
Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. Potentiation occurs with ganglionic peripheral adrenergic blocking drugs.

Medication such as digitalis may also influence serum electrolytes. Warning signs, irrespective of cause, are: dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting.

Insulin requirements in diabetic patients may be increased, decreased, or unchanged. Higher dosage of oral hypoglycemic agents may be required. Latent diabetes mellitus may become manifest during chlorthalidone administration.

Chlorthalidone and related drugs may increase the responsiveness to tubocurarine.

Chlorthalidone and related drugs may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.
From January through June 2019, participants will be requested to attend one of six sessions that will be held at the hospital simulation center. Participants will be randomized into 1 of 2 study arms. Each participant that enters the B-Con course will be randomized using a "random generator." At the start of the program, all participants will be explained the purpose of the research study and the two groups (Control versus High Fidelity). An option will be given for participants to be able to opt out. So that our participants all have the same opportunities afforded to their colleagues, we will also offer the control group the option to participate in the high fidelity simulation at the conclusion of the entire program.

All groups will sit through the exact same B-Con powerpoint presentation by trained STB instructors. This course includes the powerpoint presentation that reviews how to call for help, assess those affected, identify the location of life-threatening bleed, apply pressure, pack a wound and/or apply a tourniquet and when to do this. Tourniquet placement is taught as is wound packing placement. Participants will each be given tourniquets to practice alongside the instructor. The presentation will cover the first hour of the curriculum. This is considered to be the standard for this course.

Upon conclusion of the course, the control group and high fidelity group will be separated into two rooms based on their randomization. In groups of 2, participants will be trained in tourniquet placement, wound packing. The High Fidelity group will have a simulation intervention in addition and the wound packing will be performed on a device that has biofeedback. Upon conclusion of this one hour session, both groups will be tested on wound packing and tourniquet placement. They will again be tested 3-8 months later on retention for wound packing and tourniquet placement.
A composition for use in treating rosacea, the composition comprising a first component comprising a substituted or unsubstituted diindolylmethane (DIM) compound; and (b) optionally a second component comprising a substituted or unsubstituted retinoid compound. Preferably the diindolylmethane compound is 3,3-diindolylmethane or 2,2-diindolylmethane. The retinoid compound is preferably vitamin A palmitate. Preferably the rosacea is selected from pustular rosacea, papulopustular rosacea, erythemato-telangiectatic rosacea, granulomatosus rosacea, rosacea conglobata, rosacea fulminans and phymatous rosacea. A formulation comprising 75mg DIM, 200Âµg vitamin A palmitate, 175mg tri-calcium phosphate, 20mg microcrystalline cellulose, 11.5mg vitamin C, 10mg fumed silicon dioxide and 6mg magnesium stearate for use in treating rosacea is exemplified. A substituted or unsubtituted diindolylmethane compound (DIM) for use in treating rosacea is also provided.
BACKGROUND: Male circumcision (MC) is a practice involving the surgical excision of the foreskin to expose the glans and it is often performed for religious reasons. Ritual circumcision is frequently carried out by unqualified practitioners in inadequate settings, which can also lead to the death of the individual.
CASE REPORT: A 28-day-old infant was undergoing circumcision by a man that performed the circumcision using a razor blade. During the same day, the child experienced continuous bleeding from the wound and, finally, died after about 20 hours. At autopsy, a cutaneous sharp injury was revealed with ablation of the foreskin and part of the penile body. The lesion had irregular and jagged margins, with diffuse hemorrhagic infiltration. The glans and upper fascia of the penis appeared edematous and hyperemic and there were abundant hemorrhagic infiltrations in the frenulum area. The child's death was attributed to hemorrhagic shock in a child undergoing genital mutilation surgery. The finding of a significant hemorrhagic infiltration of the frenulum region indicated that the frenular artery had been severed.
CONCLUSIONS: Around 35% of ritual male circumcisions are performed clandestinely in Italy, and typically by unqualified practitioners. In such events, the forensic investigation of the injuries inflicted on the victim allows for determining whether the procedure was performed appropriately or not, to verify the existence of a causal link between the procedure itself and the death of the individual.
Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of several haematological malignancies and is being investigated in patients with various solid tumours. Characteristic CAR T cell-associated toxicities such as cytokine-release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are now well-recognized, and improved supportive care and management with immunosuppressive agents has made CAR T cell therapy safer and more feasible than it was when the first regulatory approvals of such treatments were granted in 2017. The increasing clinical experience with these therapies has also improved recognition of previously less well-defined toxicities, including movement disorders, immune effector cell-associated haematotoxicity (ICAHT) and immune effector cell-associated haemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), as well as the substantial risk of infection in patients with persistent CAR T cell-induced B cell aplasia and hypogammaglobulinaemia. A more diverse selection of immunosuppressive and supportive-care pharmacotherapies is now being utilized for toxicity management, yet no universal algorithm for their application exists. As CAR T cell products targeting new antigens are developed, additional toxicities involving damage to non-malignant tissues expressing the target antigen are a potential hurdle. Continued prospective evaluation of toxicity management strategies and the design of less-toxic CAR T cell products are both crucial for ongoing success in this field. In this Review, we discuss the evolving understanding and clinical management of CAR T cell-associated toxicities.
<P>PROBLEM TO BE SOLVED: To provide a new gene associated with the neuralization induction of a vertebrate animal, a protein of the same and also the use of them.  <P>SOLUTION: This XMAN1 gene associated with the neuralization induction of animal cap of Xenopus is isolated and the structures of the XMAN1 gene and XMAN1 protein are determined. Through the functional analysis of the XMAN1 gene and XMAN1 protein, the molecular mechanism of form development by the neuralization induction in the vertebrate animal can be elucidated. Also, human MAN1 which is a human homolog protein of the XMAN1 protein, may have a possibility of similar utilization. Further, the invention can be applied for the treating agent or treating method, etc., of the diseases of nervous system.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Subjects aged between 30 and 60 years old (male and female) with Type 2 diabetes mellitus (T2DM) will be recruited for this study. A randomized, crossover, double-blind study design will be carried out to investigate the acute effects of high fat meals prepared using palm olein (PO), chemically interesterified palm olein (IPO) and high oleic sunflower oil (HOS) (control) on study subjects with T2DM. Study subjects will have to undergo three postprandial challenges, separated by at least one week interval. Fasting blood sample and duplicate baseline blood samples will be taken in the morning of postprandial day. After that, subjects will be asked to consume a test meal consisting a high fat muffin baked using the aforementioned oils and a milkshake within 10 minutes. After meal, venous blood samples will be taken at time-points 15, 30, 60, 90, 120 min, 3 h, 4 h, 5 h, 6 h and post-heparin plasma 5 min and 15 min for analysis. Pulse wave analysis will be conducted to evaluate central blood pressure and arterial stiffness. Meal appreciation will be assessed by utilising visual analogue scale (VAS) before eating, after eating and at each time-point.
This group will follow the referral scheme for three months, and after this period they will leave new blood samples and answer surveys. They will get a new PAP with follow up after another 3 months.
ABSTRACT       The present invention is directed to a composition comprised of a co-precipitation of a relatively solvent-soluble organic material and a relatively solvent-insoluble organic material, said relatively solvent-soluble organic material being selectively dissolved to produce a void-containing particle.  In a preferred embodiment, the voids are filled with air.  A preferred relatively solvent-soluble organic material is carboxylic acid such as benzoic acid, salicylic acid, or diatrizoic acid.  A preferred relatively solvent-insoluble organic material is an ester of diatrizoic acid, such as the ethyl ester thereof.      The present invention is further directed to a method of making a void-containing particle, comprising co-precipitating a relatively solvent-soluble organic material and a relatively solvent-insoluble organic material under conditions and for a time sufficient to form a co-precipitate, and contacting said co-precipitate with a solvent for a time and under conditions sufficient to dissolve said relatively solvent-soluble organic material to form a void-containing particle.  In a preferred embodiment, the void-containing particle is freeze-dried for a time and under conditions sufficient to fill said voids with air.      The present invention is further directed to a method of diagnosis comprised of administering to a mammal a contrast-effective amount of a void-containing or air-containing particle described above, and generating a diagnostic image of said mammal.
PURPOSE OF REVIEW: The repair of bone after injury requires the participation of many different immune cell populations, which are derived from the hematopoietic lineage. The field of osteoimmunology, or the study of the interactions between bone and the immune system, is a growing field with emerging impact on both the basic science and clinical aspects of fracture healing.
RECENT FINDINGS: Despite previous focus on the innate immune system in fracture healing, recent studies have revealed an important role for the adaptive immune system in bone repair. The composition of adaptive and innate immune cell populations present at the fracture site is significantly altered during aging and diet-induced obesity, which may contribute to delayed healing. Recent data also suggest a complicated relationship between fracture repair and systemic inflammation, raising the possibility that immune populations from distant sites such as the gut can impact the bone repair process.
SUMMARY: These findings have important implications for the treatment of fracture patients with antibiotics or anti-inflammatory drugs. Furthermore, the effects of systemic inflammation on fracture repair in the contexts of aging or obesity should be carefully interpreted, as they may not be uniformly detrimental.
PURPOSE: To obtain a medicinal composition containing a 3-substituted-2- oxyindole-1-carboxiamide or a basic salt thereof and capable of inhibiting interleukin-1 biosynthesis in an mammalian animal. CONSTITUTION: This medicinal composition contains a compound of the formula (X is H, Cl or F; Y is H or Cl; R is benzyl or thienyl) or a basic salt thereof as an active ingredient and preparations are made by a usual method. The composition can be administered by orally or non orally, and the amount of administration is 40-200mg daily in the case of the oral administration and 1-250mg daily in the case of the non oral administration. The composition is useful for the treatment of a metabolic disorder of a bone and a connective tissue (e.g.; osteoporosis, periodontitis), and an immune functional disease (e.g.; allergy, psoriasis), etc.
All patients randomized to the intervention group had one to one yoga sessions with yoga therapist twice a week for 45 minutes on secure virtual platform. Patients were encouraged with home practice to follow everyday at least for 30-mins.
The governments of Peru and Ecuador signed an agreement with the Global Fund to Fight AIDS, Tuberculosis, and Malaria to help guarantee comprehensive quality of care to people living with HIV, including access to antiretrovirals (ARVs). Current methods of surveillance are inadequate in estimating the true burden of disease. Broad access to ARVs in countries without regular drug resistance testing can also cause rapid development of ARV resistance. By establishing a more sophisticated surveillance system able to capture HIV incidence, prevalence, patterns of HIV resistance, and genetic variability of viral strains, Peru and Ecuador will be better equipped to monitor the HIV epidemic, develop personalized prevention and control measures, and track patterns of HIV resistance among infected patients. This study will estimate the incidence of HIV, syphilis, and herpes simplex virus 2 (HSV-2) among MSM in Peru and Ecuador, as well as examine the number and variability of ARV-resistant HIV strains.

This study will last about 2 weeks. Medical history, a physical exam, an HIV rapid test, and HIV pre- and post-test counseling will occur at study entry. Those who test HIV positive will be asked to return to the test site in about 2 weeks to receive confirmatory test results. Patients confirmed to be infected with HIV will be referred to HIV treatment clinics in their area.

At study entry, participants will also undergo a syphilis test. Those who test positive for syphilis will receive same-day treatment at the clinic and be asked to return during Week 1 and 2 to complete treatment for sexually transmitted diseases (STDs) according to local guidelines. STD treatment will not be provided by the study. Those who test negative to both the HIV rapid test and the syphilis test at screening will not participate in any more study visits. Patients who consent to having samples stored for further investigations will also have their samples tested for HSV-2 infection following completion of the study.
Although high titers of neutralizing Abs in human serum are associated with protection from reinfection by SARS-CoV-2, there is considerable heterogeneity in human serum-neutralizing Abs against SARS-CoV-2 during convalescence between individuals. Standard human serum live virus neutralization assays require inactivation of serum/plasma prior to testing. In this study, we report that the SARS-CoV-2 neutralization titers of human convalescent sera were relatively consistent across all disease states except for severe COVID-19, which yielded significantly higher neutralization titers. Furthermore, we show that heat inactivation of human serum significantly lowered neutralization activity in a live virus SARS-CoV-2 neutralization assay. Heat inactivation of human convalescent serum was shown to inactivate complement proteins, and the contribution of complement in SARS-CoV-2 neutralization was often >50% of the neutralizing activity of human sera without heat inactivation and could account for neutralizing activity when standard titers were zero after heat inactivation. This effect was also observed in COVID-19 vaccinees and could be abolished in individuals who were undergoing treatment with therapeutic anti-complement Abs. Complement activity was mainly dependent on the classical pathway with little contributions from mannose-binding lectin and alternative pathways. Our study demonstrates the importance of the complement pathway in significantly increasing viral neutralization activity against SARS-CoV-2 in spike seropositive individuals.
Bioadhesive formulations to deliver, for both local and systemic effects, a wide variety of drugs of varying degrees of solubility are described. These formulations can be gels or aerosols and comprise a water-insoluble, pharmaceutically acceptable alkyl cellulose, a solvent system comprising a volatile solvent and water, a solubilizing agent or a dispersing agent, or a mixture thereof, and a pharmaceutical. These formulations can be made bioerodible and release the pharmaceutical in a controlled manner. Formulations further comprising a propellant such as 1,1-difluoroethane are also provided. The delivery can be made to a skin surface or to a mucosal surface. Methods for preparing and administering these formulations are also provided. Several specific examples using the anti-ulcer medication 2-amino-7-(1-methylethyl)-5-oxo-5H-[1]benzopyrano-[2,3-b]-pyridine-3-carboxylic acid are provided.